LFG
CAPR icon

Larson Financial Group’s Capricor Therapeutics CAPR Stock Holding History

Larson Financial Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$987 Sell
41
-29
-41% -$879 ﹤0.01% 3318
2026
Q1 		$2.13K Buy
+70
New +$1.86K ﹤0.01% 2942

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Larson Financial Group's CAPR Position: Q2 2026 in Review

Larson Financial Group reduced its Capricor Therapeutics (CAPR) stake by 41% in Q2 2026, selling an estimated $879 and leaving 41 shares worth $987. The position accounts for ﹤0.01% of the portfolio, ranked #3318.

Larson Financial Group first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.13K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Larson Financial Group held 41 shares of Capricor Therapeutics worth $987 as of Q2 2026.
  • Larson Financial Group sold 29 Capricor Therapeutics shares in Q2 2026, an estimated $879.
  • Capricor Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3318 holding.
  • Larson Financial Group first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Larson Financial Group's Capricor Therapeutics position peaked at $2.13K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.